Use our `search` to find similar offers.
Assistant Report Co-ordinator
Charles River Laboratories International Inc (CRL)
Tranent, GB, EH33 2NE
For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.
Job Summary
The above vacancy now exists in our Administration & Reporting Team based at our World Class facility in Tranent, near Edinburgh.
In the role of Assistant Report Co-ordinator, you will work collaboratively with the Study Directors to schedule and assist in the reporting of a variety of studies using the Report Monitoring System (RPM).
Key Responsibilities:
- Assisting with the scheduling of all study reports on site
- Liaising with all departments to negotiate and propose schedules based on various study designs.
- Monitoring studies in our RPM in-house report monitoring system to ensure reports are sent accurately and on time.
- Following up on late reports and completing the reasons for delays in RPM
- Generating management information reports.
Applicants must have excellent attention to detail and the ability to manage multiple and varied tasks. You will have the ability to efficiently and independently to tight deadlines while communicating effectively to enable you to build and hold good working relationships with a broad range of key staff. Finally, the successful applicant will have proven working experience of recording data accurately with strong IT skills, specifically with MS Work Excel packages.
Salary for this position will be on £24,638.06 per annum dependent upon qualifications and/or relevant experience.
Closing date is 15 May 2024.
About Safety Assessment Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market. Each year approximately 300 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.
About Charles River Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.
Job posted: 2024-05-02
